← Back to Clinical Trials
Recruiting NCT06930560

NCT06930560 HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06930560
Status Recruiting
Phase
Sponsor Johns Hopkins University
Condition Alzheimer Disease
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2025-10-15
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age 100 Years
Study Type INTERVENTIONAL
Interventions
HEARS-NPS deviceHEARS-NPS program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2025-10-15 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial study aims to evaluate a revised hearing care intervention for older adults with Alzheimer's Disease and Related Dementias (ADRD). The community-delivered hearing care intervention utilizes tailored strategies to assess impact on communication, neuropsychiatric symptoms (NPS), and care partner distress.

Eligibility Criteria

Inclusion Criteria: * Age 60 - 100 years old * English-speaking * Diagnosis of probable Alzheimer's Disease or other related dementia according to the core clinical criteria outlined in the National Institute on Aging (NIA) and Alzheimer's Association Guidelines * Speech frequency pure tone average (0.5- 4 kHz) \>25 db in the better-hearing ear; adult onset hearing loss * Availability of caregiver/study partner who is 18+ to participate in all study-related visits and who provides care supervision * Stable (for 2 weeks or longer) dosing of medication (e.g. antidepressants, antipsychotics) for neuropsychiatric symptoms Exclusion Criteria: * Current self-reported use of hearing aid or amplification device * Medical contraindication to use hearing aids ( e.g. draining ears) * Inability to participate in the 1-month follow up

Contact & Investigator

Central Contact

Esther Oh, MD, Ph.D.

✉ eoh9@jhmi.edu

📞 410-550-0925

Principal Investigator

Esther Oh, MD, PhD

PRINCIPAL INVESTIGATOR

Johns Hopkins University

Frequently Asked Questions

Who can join the NCT06930560 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, up to 100 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06930560 currently recruiting?

Yes, NCT06930560 is actively recruiting participants. Contact the research team at eoh9@jhmi.edu for enrollment information.

Where is the NCT06930560 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT06930560 clinical trial?

NCT06930560 is sponsored by Johns Hopkins University. The principal investigator is Esther Oh, MD, PhD at Johns Hopkins University. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology